



+ ————— #CEBioForum2023

bio
forum
Central European

we create **biotech** world

Keep this catalogue also in digital version:



#CEBioForum2023

What CEBioForum will bring you this time?

b

B2B meetings with
representatives of biotech
companies on Day 1+2 | page 14

a

CEBioForum Awards 2023 contest
during banquet on Day 1 | page 16

i

Inspiring discussions during panel
sessions on Day 1 | page 30

b

BioTech Pitch on Day 1 in front
of industry investors | page 40

p

BioTech Presentations on Day 1
| page 43

l

Lectures on Day 2 by experts
in biotech field | page 50

Let other know you are here!



+ ————— tag & post
your presence with #CEBioForum2023

&

follow us
Central European BioForum



dr Magdalena Kulczycka
Director of CEBioForum



Ladies and gentlemen,

I am pleased to welcome you to the next edition of CEBioForum organized by the Association of Biotechnology Companies BioForum. After a spectacular return to stationary form last year, we do not stop and here we are again in the capital of Poland at the most renowned biotechnology event – Central European BioForum 2023.

During this year's edition, I hope you will enjoy two days filled with: discussion panels on various topics from the life science industry, B2B meetings, Biotech Presentations and Biotech Pitches, during which biotechnological companies will have a chance to present their achievements. Last, but not least – we will reward outstanding projects and people who contributed last year to biotech development with CEBioForum Awards 2023 in 4 categories.

CEBioForum continues its mission in creating networking opportunities for scientists, investors, entrepreneurs and decision-makers involved in building up innovations in the biotechnology sector, as we believe this is a necessary element for effective brainstorming that contributes to the further development of biotechnology.

Thank you for being with us as partners, guests, participants and co-creators of this event and I would like to invite you to contribute to #polishbiotech development as members of the Association of Biotechnology Companies BioForum, as together we can make the difference.

Magdalena
Kulczycka

we thank our ———
partners

#CEBioForum2022
we thank our 2023 partners!

bio
forum
Central European





JAGIELLONIAN CENTER OF INNOVATION

was founded by the Jagiellonian University in Cracow, one of the most recognisable university in this part of Europe. JCI is firmly rooted in two pillars of its competences: **the business mode of operation** (agility, speed, timeliness and, above all, quality), and the scientific and **research aspects of its projects and services**.


CARRYING OUT LABORATORY TESTS IN ACCORDANCE WITH CUSTOMER EXPECTATIONS, BOTH THOSE TAILOR-MADE AND THOSE CARRIED OUT IN ACCORDANCE WITH STRICTLY DEFINED STANDARDS

IMPLEMENTATION OF CLINICAL TRIALS BASED ON THE PROTOCOLS AND STUDY PLANS PROVIDED

MANUFACTURE OF MEDICAL DEVICES, COSMETICS AND CERTAIN FOOD SUPPLEMENTS


EXPERT ADVICE IN THE AREA OF LABORATORY TESTING

PRODUCT DESIGN AND RESEARCH SUPPORT



CLINICAL
TRIALS

MEDICAL
DEVICES



QUALITY
POLICY



COSMETICS



The National Centre for Research and Development

The National Centre for Research and Development (NCBR) is a government agency that connects the world of science and business. It creates the right conditions for research and development (R&D). By co-financing R&D processes, it supports domestic entrepreneurs, significantly reducing their business risk accompanying the implementation of breakthrough research projects.

The mission of NCBR is to implement tasks serving the social and economic development of Poland and to solve specific civilization problems of its inhabitants. NCBR is a centre for supporting and developing innovative technological and social solutions, creating an ecosystem of knowledge of, and information about, innovation. It organises and implements undertakings contributing to the civilization growth of the country.

NCBR implements a number of national and international programmes in areas such as green deal, artificial intelligence, medicine, biotechnology, as well as projects related to state security and defence. In the years 2008-2022, we allocated over PLN 70 billion to support R&D works of Polish enterprises, start-ups, universities and research institutes.

The activities of the National Centre for Research and Development are characterized by three components: 'Risk', 'Balance' and 'Result'. Our horizon is not a race, how many contracts we will manage to sign, but constant monitoring of how much the Polish economy will gain from their implementation, and indirectly every citizen. We create the world of Polish innovation. We are building modern present times and future.

gov.pl/ncbr

The National Centre for Research and Development

THE FUTURE IS HAPPENING HERE

NCBR

National Centre for Research
and Development

**save
the date for
#CEBioForum2024
26-27 March
_____ Warsaw**

next edition

Sign up to our newsletter to be up-to-date with upcoming #news:
www.cebforum.com

18-19 April —
agenda

DAY 1

#CEBioForum2023

first day event schedule

bio
forum
Central European

Panel Sessions | 18.04.2023 - day 1

MAIN STAGE

8.30 - 9.00

Registration

9.00 - 10.00

Opening + K E Y N O T E

10.00 - 11.00

P A N E L

Development of the biotech
industry in Europe

11.00 - 11.30

Coffee break

11.30 - 12.30

P A N E L

Potential of the
biotech market in Poland

12.30 - 13.30

Lunch

13.30 - 14.30

P A N E L

Investments in biotech

14.30 - 15.30

P A N E L

How ESG influences biotech
companies?

15.30 - 15.45

Coffee break

15.45 - 16.45

P A N E L

New technologies in biotech

18.30 - 23.00

CEBioForum Awards 2023 Banquete

SIDE STAGE

11.30 - 13.00
BioTech Pitch

14.00 - 15.15
BioTech
presentation

15.45 - 16.45
BioTech
presentation

#CEBioForum2023

second day event schedule

Panel Sessions | 19.04.2023 - day 2

LECTURES

8.30 - 9.00

9.00 - 10.00 McDermott Will&Emery

10.00 - 11.00 Wardyński&Partners

11.00 - 11.15 Coffee break

11.15 - 12.15 EIT Health

12.15 - 13.15 Polpharma Biologics

13.15 - 14.00 Lunch

14.00 - 15.00 CRIDO

15.00 - 16.00 Mabion

#CEBioForum2023

B2B meetings

arrange them on-line
via networking platform

In cooperation with Klaster Lifescience Krakow we bring to you networking platform <https://www.lifescienceopenspace.com/> where you can sign up & arrange B2B meetings within CEBioForum2023 group.


There you will find:



an agenda for the 2 days of the event



place where B2B meetings are taking



**B2B
zone**

Where can
you meet?

CEBioForum —
awards

#CEBioForum2023

CEBioForum Awards 2023

CEBioForum Awards is a prestigious competition rewarding the achievements of biotechnology companies and people from Central Europe. The Award ceremony takes place during banquet on 18th of April.

The contest aims to select the best or most innovative solutions or enterprises in 4 categories:

r

R&D Collaboration

m

Most Influencing Person

i

Innovative Start Up

j

Jury Award



#CEBioForum2023

The jury of the **CEBioForum Awards 2023** consists of:



Prof. Magdalena Król - Member of the Board at Cellis Ltd.

At the age of 37, she became a full professor at Warsaw University of Life Sciences. She is a co-founder and Member of the Board of the 'Cellis' company which operates in Poland and Switzerland. Company develops innovative macrophage therapy of solid tumors, focusing on unmet medical need tumors: glioblastoma, ovarian cancer and pancreatic cancer. In 2020 she was shortlisted finalist in EU Prize for Women Innovators Award.



Beata Szparaga-Waśniewska - Healthcare Equity Research at mBank

Sell-side equity research analyst with 13 years of experience. Coverage of multiple sectors including Central Eastern Europe biotechnology and healthcare stocks. Ranked #1 in healthcare in Polish Parkiet daily sell-side analyst ranking in the years 2020-23. Leading research analyst in several IPO/SPO transactions such as Selvita, Ryvu Therapeutics, Celon Pharma, PolTREG. CFA

charterholder, Licensed Investment Advisor. Graduate of the Warsaw School of Economics and Gdansk University.

#CEBioForum2023

The jury of the **CEBioForum Awards 2023** consists of:



Robert Florczykowski - Partner at Third dot

Co-founder and portfolio manager of the investment fund Third Dot within Opoka TFI S.A. as well as Supervisory Board member of Captor Therapeutics, biopharmaceutical company focused on development of protein degradation drugs. Previously he managed global funds investing in technology and healthcare sector within the PKO TFI S.A. Robert Florczykowski graduated from the faculty of

"Quantitative Methods in Economics" at the Warsaw School of Economics and "Mathematics" at the University of Warsaw. He also completed postgraduate studies in "Molecular Biology" at Jagiellonian University and "Postgraduate Studies in Accounting and Finance" at Warsaw University of Technology Business School.



Paweł Wielgus, Ph.D. - Member Of The Management Board at Bioceltix / Kvarko Investment Fund

co-founder and board member of Bioceltix, CEO of Kvarko Investment Fund, an investor in early-stage companies (including Bioceltix, QNA Technology, SatRev, DEBN, Alphamoon, Green Zebras). M.Sc. in Biotechnology (Wrocław University of Technology), Ph.D. in

chemical sciences (Wrocław University of Technology), financial analyst (Wrocław University of Economics).

#CEBioForum2023

The jury of the **CEBioForum Awards 2023** consists of:

Scholarship holder at the Max Planck Institute for Solid State Physics in Dresden, author of scientific papers in the field of quantum chemistry published in prominent professional journals, certified advisor in the New Connect alternative trading system, and former member of supervisory boards of listed companies. He has extensive and practical experience in the investment fund market and establishing and managing technology companies.




Aleksander Kłósek - Managing Partner in YouNick Mint

Managing Partner at YouNick Mint VC. Focused on seed and early-stage investments in healthcare & digital healthcare space. 15+ years of experience in pharmaceutical sales management and venture investment in healthcare, digital healthcare, pharma, food tech and industry 4.0. Led or participated in 30+ capital investments and exit transactions, including sale of 100% of shares of SmartPharma portfolio company to global pharmaceutical company. Passionate about working with entrepreneurs, scientists and medical experts to create unique value within the innovative tech companies for clients and investors. MS in Psychology and MBA graduate. Privately an avid traveller!

#CEBioForum2023

Map of Polish biotechnology startups



Polish companies for at least 3 years and active in biotechnology and/or R&D in the field of life science or using the achievements of genetic engineering and bioengineering in technological processes were included. Location determined on the basis of data in the National Court Register.

#CEBioForum2023

Join #polishbiotech database by the Association of Biotechnology Companies BioForum

Our goal is to support #networking in the biotech industry - that's why we have created a database of biotech companies.

**bio
forum**

Związek Firm Biotechnologicznych



#cebioforum
we create
**biotech
world**


submit
your company with
this link

our

speakers



Opening session



Cooperation is the key for success therefore we are proud to highlight the presence of representatives of Lithuanian and Polish government during opening of Central European BioForum 2023.



Waldemar Buda

Minister of Economic Development
and Technology of the Republic of Poland

Aušrinė Armonaitė

Minister of the Economy and Innovation
of the Republic of Lithuania





Key note speaker



Key note speaker



Michael Soldan

CEO of Polpharma Biologics Group

18th of April 2023, 9.15

Michael Soldan has over 20 years experience on his professional development path in the pharmaceutical industry. He heads Polpharma Biologics, a company focusing on development and production of biological drugs, one of the fastest growing in the region, after he has vast expertise in Executive Management in companies like Merck Group, Fresenius Kabi, AB2Bio.

He worked as scientist in Pharmacology.

He has a deep understanding of biosimilars and has an impressive background of Life Science - gaining his experience in Clinical Research, Protein Chemistry, Vaccines and Oncology.



symbioza

Warszawskie Stowarzyszenie Biotechnologiczne
„Symbioza”



Warsaw Society of Biotechnology
„Symbioza”



@wsbsymbioza



Visit our site:



Science Popularization Integration



Symbioza Umysłów

XENSTATS

SCIENTIFIC SOFTWARE HOUSE

· Software Development

Our team consists of scientists and senior developers who program in R, Python and Java and have experience in machine learning, artificial intelligence and advanced bioinformatics software development. We specialize in developing software for life sciences, especially in the fields of metabolomics, proteomics, genomics, transcriptomics and lipidomics.

· AI Solutions

We develop a comprehensive strategy for adapting AI to business needs, along with identifying those needs and indicating methods of implementing solutions. AI implementation is therefore based on real needs, in order to reduce costs and increase efficiency.

· Bioinformatics Analyses

We specialize in complex statistical analysis of chemical and biological data, particularly of chromatographic, next-generation sequencing and phenotypic data. Our skills enable us to effectively analyze RNA-seq data, as well as chromatographic data originating from a large variety of devices (LC-MS, GC-MS, LC-UV, LC-FLR) performed in different experimental designs.

· Competencies Outsourcing

Life sciences projects require experts from various fields of expertise and hiring employees on a full-time basis for every project can be very expensive. We can provide you with the services of the best specialists (Ph.D. and Professor level) from many fields of life sciences (biology, chemistry, biotechnology, statistics, machine learning, bioinformatics) working on your project only when they are needed.

· Our Clients

We cooperate with nearly 40 institutes and universities in Poland as well as companies implementing projects that require specialized scientific and programming knowledge.

· Let's Talk

Aneta Sawikowska, Ph.D., D.Sc., Associate Professor
CEO & Founder
mobile: +48 606 611 914
e-mail: aneta.sawikowska@xenstats.com



panel _____
sessions

Panel title: Development of the biotech industry in Europe

Date: 18th of April 2023

Place: MAIN STAGE

Time: 10:00 - 11.00

Moderator: Jan Filip Staniłko - NASK Research Institute, Director of Strategy

Topics covered: The Biotech business is one of the most attractive markets, but at the same time very specific when it comes to development. During this panel we will talk about perspectives for European biotech on the global scene and how we can compete with other regions. Considering the growing market is also important to know our strong and weak aspects and what are the most efficient ways of cooperation for the EU.

Speakers at the panel session:

- > **Aušrinė Armonaitė** - Minister of the Economy and Innovation of the Republic of Lithuania
- > **Claire Skentelbery** - EuropaBio/ General Director
- > **Danuta Mossakowska** - Earnshaw - Małopolskie Center of Biotechnology JU/ Director
- > **Barbora Šumová** - i&i Biotech Fund, Prague/ Senior Associate
- > **Tomas Andrejauskas** - Lithuania Biotech Association/ President
- > **Andrzej Ryś** - DG Sante, European Commission/ Principal Scientific Advisor

Panel title: Potential of the biotech market in Poland

Date: 18th of April 2023

Place: MAIN STAGE

Time: 11.30-12.30

Moderator: Karolina Jarosińska - Exec Mind/ Managing Director

Topics covered: The Polish biotech industry has come a long way in the past 15 years. There are now 170 companies, with over 5,000 employees involved in research and development including academic research centers. During this session there will be a discussion about the current situation in the biotech industry and perspectives. Also speakers will pay attention to Polish biotech strengths and weaknesses and to sum up they will answer the question of what needs to be changed to expand companies potential.

Speakers at the panel session:

- > **Marlena Tryka** - Ministry of Development and Technology RP/ Director of the Department of Innovation and Industrial Policy
- > **Mariusz Olejniczak** - WPD Pharmaceuticals/ CEO
- > **Adam Pietruszkiewicz** - Mabion/ CCO
- > **dr Maciej Wieczorek** - Celon Pharma/ CEO
- > **Piotr Korycki** - Polpharma Biologics/ CEO
- > **dr hab. inż. Agnieszka Jastrzębska** - Technical University of Warsaw

Panel title: **Investments in biotech**

Date: 18th of April 2023

Place: MAIN STAGE

Time: 13.30-14.30

Moderator: Michał Ficenes - Ipopema TFI/ Portfolio Manager

Topics covered: Investing in biotechnology is not easy. Biotechnology in Poland is still in its infancy and may achieve greater success than many can imagine. However, without deep analysis, it is difficult to earn anything. During the panel speakers will show how to analyze investments in biotechnology. How liquid is the market after the crisis and which market in biotechnology is better - private or public? Key leaders will also speak about financing options and their control, and what areas of biotechnology are worth investing in.

Speakers at the panel session:

- > **Łukasz Kościjańczuk** - CRIDO/ Partner
- > **Dan Akschuti** - Pareto Securities/ Equity partner and Life Science Analyst
- > **Robert Aleksandrowicz** - Twiti Investments/ Investor and Co-Founder
- > **Rozalia Urbanek** - PFR Ventures/ Investment Director
- > **Ksenia Wójcik-Karasiewicz** - NCBIr/Expert

Panel title: How ESG influences biotech companies?

Date: 18th of April 2023

Place: MAIN STAGE

Time: 14.30-15.30

Moderator: Paweł Oksanowicz - Journalist covering sustainability, ESG & business ethics

Topics covered: ESG (Environmental, Social and Corporate Governance) is a concept that has been used more and more recently. Speakers will discuss about social responsibilities of big companies and how novel regulations influence BD of companies. Will they actually contribute to the Green deal and environmental protection? Also during this panel they will pay attention to a recent problem - availability of drugs.

Speakers at the panel session:

- > **Paulina Kapuścińska** - Pelion/ Director Public Affairs
- > **Joanna Krakowiak** - Wardyński i Wspólnicy/ Head of Life Sciences and Healthcare Practice
- > **Konrad Hennig** - BioForum/ Member of the Board
- > **Tomasz Poniński** - Montis Capital/ Founder & Managing Partner
- > **Maciej Plebanek** - Pfizer Polska/ Medical Director, IM Medical Lead Poland

Panel title: **New technologies in biotech**

Date: 18th of April 2023

Place: MAIN STAGE

Time: 15.45-16.45

Moderator: Magdalena Kulczycka - BioForum / Director

Topics covered: New technologies are always a huge breakthrough, but they are also shrouded in mystery. During this panel speakers will reveal to us a veil of that secret including CRISPR, spatial biology and synthetic biology. They will answer the question: is non-coding RNAs are biomarkers of the future and what is ATMP drug development.

Speakers at the panel session:

- > **Aleksandra Włodek** - Constructive Bio, UK/CEO
- > **Marek Postuła** - Medical University of Warsaw/ I-COMET research team/ M2M advisors/ Professor, Co-Owner
- > **Zuzanna Stern** - Cellivia 3 S.A./ CEO
- > **Agnieszka Gawda** - Polonium Foundation/ Vice-President & CBO
- > **Angelo Da Rosa** - Lunaphore, UK/ Technical Sales Specialist
- > **Dominik Lipka** - SyVento/ R&D Director

Polpharma Biologics is a biotechnology group active in the field of development and manufacturing of biologics. The first Polish company to manufacture a biosimilar drug that has been approved both by the FDA and EMA. **Polpharma Biologics** has been active for more than 10 years pursuing R&D operations on a scale unprecedented in the Polish biotechnology sector. The group has been consistently investing not only in laboratories and production lines, but also in building the know-how to create highly specialized job opportunities and forging closer bonds of cooperation between the scientific and business communities.

By using modern cell line development platforms, **Polpharma Biologics** is focused on creating biosimilars to treat a range of conditions in important therapeutic areas such as neurology, immunology and ophthalmology. The current pipeline contains more than six biosimilars in different stages of development. Polpharma Biologics stands out with its capacity and expertise to run the entire development process for a biologic drug starting from the cell line development, through establishing analytical methods, process characterization, scale up right to manufacturing the active substance on an industrial scale and finally providing medicines ready for commercial partnerships with global pharmaceutical companies.

A team of more than 1000 experts stands behind **Polpharma Biologics**, with more than 10% of the team holding PhD degrees. The company operates in three centers which are among the most advanced in Europe:

- Development & Production Center in Gdansk, Poland
- Development & Production Center in Warsaw-Duchnice, Poland
- Research & Development Center in Utrecht, the Netherlands.

POLONIUM FOUNDATION

POLONIUM NETWORK

For over 10 years the Polonium Foundation has been working on behalf of Polish scientists in the country and abroad. From its early days the Polonium Team focused on organising Conferences and Meetups Science: Polish Perspectives (SPP) at leading Universities and research institutions. SPP is a series of events that connects Polish scientific diaspora from all over the world in order to understand them better, support the networking of its members and provide them with a platform to raise important issues with the R&I environment, policy makers and industry sector in Poland. All SPP events promote interdisciplinarity and scientific popularisation best practices.

To cultivate the long term growth of the community of Polish students, postdocs, professors, industry professionals, entrepreneurs, innovators and all other highly qualified subject matter experts with Polish roots, Polonium Foundation has created the Polonium Network. Polonium Network, operating since 2020, is a virtual platform that gathers our community as well as provides access to job offers, mentors/advisors, support in grant applications, and Career Café webinars.

Apart from the science popularisation efforts, Polonium Foundation has the largest base and trust of the scientific community. We run our own research and index multidisciplinary polish researchers in Poland and globally. In the past few years they have published reports focusing on Polish highly educated professional expats: ***Beyond recognition: Polish scientific diaspora as a source of social capital*** and ***Approaches towards Brexit among Polish researchers in the UK*** Recently the Foundation has also launched a research project on the current and future UK-Polish research & innovation relationship in partnership with Science and Innovation Network (SIN) Poland and the British Embassy in Warsaw.

We welcome Collaborations and Partnerships form with Polish companies and institutions that want to tap into the international potential and social capital encapsulated in the Polish scientific diaspora, both - in Poland and abroad.

Join Polonium Network today!



PAIH for polish biotechnology

We are committed to promoting Poland and the Polish economy. We aim to increase the awareness of Polish brands on international markets. We promote National products and services, as well as Polish innovative Information technology. We help entrepreneurs select their optimal foreign expansion path.

PAIH's Offer for Exporters:


- Analysis for export potential
- Preparing and verifying lists of possible potential partners them
- Developing strategies for expansion in selected markets
- Organizing B2B meetings
- Organizing business missions

Check what else we have on offer www.paih.gov.pl



day 1 ——— 18/04

biotech pitch & presentations



#CEBioForum2023

BioTech Pitch



BioTech Pitch

Taiwania Fund

Taiwania Capital is a venture capital firm founded in August 2017 by the National Development Fund of the Executive Yuan of Taiwan and private enterprises. Our mission is to establish a partnership with companies worldwide and boost Taiwan's economic growth.

We focus on investing in early-stage companies and have managed six funds till 2022.

We focus on financial returns, but more than that, by linking technology and capital, we aspire to create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.

Neo-Antigen Biotechnology Ltd



BioTech Pitch

Neo-Antigen Biotechnology (NEOAG) is a start-up organization (SME) established in November 2021. NEOAG was founded by inventors of the TFR123 immunizing platform. NEOAG is licensing the IP from the University of Pécs, Hungary. The NeoAG Ltd. is currently incubated by a pre-seed investor entitled Creative Accelerator Ltd. Hungary. The organization has awarded two independent 'proof of concept' grant proposals in 2021 and 2022





BioTech Pitch

3M Hungaria Ltd.

3M Science.
Applied to Life.

3M Hungaria is reducing the weight of transmission lines so that more energy reaches more people. We help manufacturers create more with less. We automate health data so that the right information reaches the right people. Around the world, 3M inspires renewal and gives impetus to progress, while making a real contribution to the sustainable development of our planet and economy through environmental protection, corporate and social responsibility. Through science and innovation, we make a visible impact on the lives of all people around the world. The topic is a revolutionary solution for harvested cell culture fluid clarification. In recent years 3M focused on the clarification solutions in Biopharma. 3M can provide state-of-the-art solutions for the upstream and downstream processes. These products are ensuring simpler and more effective clarification strategies for the market.



AI|ffinity

BioTech Pitch

AI|ffinity
MOLECULAR DESIGN

AI|ffinity is a Czech spin-off company, which aims to develop and provide to the pharmaceutical and biotechnology markets innovative solutions to quantify protein-ligand binding affinity (hit discovery, lead optimization, off-target prediction) by AI, as well as to characterize protein-ligand interactions and determine protein 3D structures by Nuclear Magnetic Resonance (NMR). Our NMR protocol is the fastest and cheapest structure determination protocol in structural biology with potential applications in drug discovery and protein engineering. The unique combination of our technologies seeks to increase the speed, quality, and success rate of early-stage drug discovery, while dramatically reducing the costs from pursuing unnecessary experiments



BioTech Pitch

Cureline Baltic


Cureline Baltic is part of a global US-based translational and precision medicine CRO providing preclinical project management services for drug discovery in oncology, immune-oncology, metabolic and autoimmune disease therapeutic areas. Cureline Baltic biological services include extensive preclinical in vitro, ex vivo, and in vivo models with an emphasis on small animal studies, as well as molecular and histological analyses. Cureline Baltic also specializes in human biospecimen acquisition and tissue research projects including study design, regulatory affairs, clinical network management, specimen collection and analyses, and complete logistics.

ImmunoTronics

BioTech Pitch



ImmunoTronics is an early stage MedTech venture aimed at development of electrochemical/electronic biosensors for Point-of-Care diagnostics. As the first challenging project, ImmunoTronics is working on a rapid sepsis diagnostics system that utilises synergy of immunoFET technology, novel biomarker panel and AI-based predictive model. The Founders are currently looking for support as they want to exceed their activities outside the research grant framework.





BioTech Pitch

Galindia Labs



A young, Polish startup located in Olsztyn. The goal of Galindia Labs is to combat drug-resistant bacteria. To this end, he is developing phage therapies that will be used in the veterinary and human health sectors.

#CEBioForum2023

BioTech Presentation



CRYOPDP

BioTech Presentation

A young, Polish startup located in Olsztyn. The goal of Galindia Labs is to combat drug-resistant bacteria. To this end, he is developing phage therapies that will be used in the veterinary and human health sectors.





BioTech Presentation



Jerzy Haber Institute of Catalysis and Surface Chemistry of the Polish Academy of Sciences

Jerzy Haber Institute of Catalysis and Surface Chemistry of the Polish Academy of Sciences in Krakow is a leading research center in the field of catalysis and surface chemistry. Founded in 1956, the institute has a long-standing tradition of conducting fundamental and applied research on heterogeneous catalysis, surface science, and multiple related fields. With its state-of-the-art facilities and internationally renowned scientists, the institute is dedicated to advancing our understanding of catalytic processes and developing new technologies for sustainable energy and environmental applications. A new branch of science in which the institute has started intensive development are biopolymers. Thanks to obtaining grants such as Lider or TechMatStrateg from the National Center for Research and Development, it was possible to build a biorefinery module, where scientists from the Laboratory of Bioprocess Development can study and perform microbiological processes on a scale of up to 200l. This facility contributes to closer cooperation between science and industry.



BioTech Presentation FileClo



FileClo is a company collecting a devoted chemistry and biotechnology expert team heading for a breakthrough in the cancer treatment. We strongly believe in the world where non-invasive therapies are available to everyone within medical treatments and preventatively. Our results so far have proven Salinomycin to be the future of cancer treatments and our work on this substance has provided more and more selective and promising derivatives. Our main objective now is to prepare for the Phase 1 clinical trials.



SGS Vitrology BioTech Presentation

SGS Vitrology, as a world leader in biopharmaceutical testing services, we offer you a comprehensive range of biologics safety testing, including virology, cell and molecular biology, as well as microbiology and electron microscopy. As a result, we can help you to ensure product safety and meet your regulatory requirements.



BioTech Presentation The Foundation for Polish Science



The Foundation for Polish Science (FNP), active since 1991, is the largest non-budgetary source of science funding in Poland. We are a non-governmental, non-political, non-profit institution that pursues a mission to support science. The Foundation pursues its statutory goals by supporting outstanding scholars and research teams in all fields of science and supporting innovative ventures and commercialization of scientific discoveries and inventions.



BioTech Presentation

Mabion s.a

Well know polish biotech company Mabion will present it's new development strategy and capabilities as an end-to-end biologic CDMO. Join the presentation to discover new path for Mabion.

MABION



BioTech Presentation

Polyplus

Polyplus

Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro® and FectoVIR®-AAV.

Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia.

diCELLa

BioTech Presentation

diCELLa

diCELLa is a young, promising company established in 2018, which is proud to employ young IT and mathematical talents of the Jagiellonian University. The company provides its customers with the best products: dedicated solutions for laboratories, tools for analyzing microscopic images, data analysis, knowledge reports, big data, dedicated SAAS systems. diCELLa deals with advanced techniques for the analysis and interpretation of microscopic images designed for the user's convenience.

**HORIZON
europe**


BioTech Presentation

NCBR - Horizon Europe Programme

Horizon Europe is the largest European Union program for research and innovation. It tackles climate change, helps to achieve the UN's Sustainable Development Goals and boosts the European Union competitiveness and growth. It is an opportunity for companies, research institutes, universities, NGOs, public institutions to apply for grants. The projects should involve international cooperation, innovative ideas and solve important problems, challenges we are facing on every day basis in different fields such as health, energy, transport, industry, agriculture, etc. Biotech innovation will of course find place for funding in Horizon Europe. Issues like bio-based systems, bioeconomy, biotechnology are vital parts of the program enabling large amount of institutions to work on their brilliant ideas. Horizon Europe offers attractive funding model, including up to 100% funding rate of direct costs. National Contact Point for Horizon Europe in NCBR offers help to all potential beneficiaries on how to apply for funding.

day 2 — 19/04

lectures



McDermott Will & Emery Lecture

**Key Legal Issues and Pitfalls
in Licensing and Co-Development
Agreements**


In course of pharmaceutical product development, a collaboration with a strategic partner might become necessary or desirable sooner or later. A collaboration can serve different purposes, such as the conduct of joint development activities, access to additional technologies/IP or simply leveraging the product development by partnering with a knowledgeable partner who can perform and finance clinical studies, market launch or commercialization in important markets. Co-Development or Licensing Collaborations are complex legal animals, because they govern the parties' relationship and contributions over a long period of time. Just as importantly, they govern how the pie is shared between the parties if the product is successful.

In each collaboration, there are certain key issues (and potential pitfalls) which need to be taken into diligent consideration and which take up a significant share of negotiation time prior to signing of the respective agreements. The lecture will explain the economic background for these key issues, the interests of both parties (presented from each angle) and how these issues can (and should) be addressed in the agreements. The goal of the lecture is to make business development teams or inhouse counsel aware of what they should have in the back of their minds when entering into partnering

Who will lead the lecture?

Dr. Monika Richter

Advises national and international biotechnology/pharmaceuticals companies on various commercial legal matters related to the development, manufacturing and commercialization of medicinal products, with a particular focus on strategic alliances, research and development collaborations, license agreements, commercial manufacturing and supply agreements and distribution agreements. Her work likewise includes financing and corporate transactions as well as mergers and acquisitions.



Wardyński & Wspólnicy Lecture

What to think about when preparing for a transaction on the bio-tech market aimed at exiting the current investor from the investment or significant recapitalization of the company – the seller's perspective

Exiting your own investment – a company that was established as a result of the enormous effort of its founders and many sleepless nights – is not an easy thing. During the lecture, we will discuss how to prepare a company for sale and what legal elements to pay attention to when determining the strategy of conduct, so that the transaction is successful and both parties are satisfied. They will tell you what to pay special attention to in the entire process, starting from the selection of advisers, preparation of materials for due diligence analysis, taking into account the proper protection of business secrets and sensitive information, to negotiations and signing the contract. We will discuss the differences between a full exit from the investment and the sale of a majority stake with remaining in the company as a minority shareholder, and how to secure participation in the company's future profits

after full commercialization of the product. By guiding the participants of the lecture through the subsequent phases of the transaction, we will pay attention to the differences that transactions involving companies already listed on the stock exchange may have. Finally, we will also show how the planned transaction structures can include incentive programs implemented in the company for the company's key management staff based on the company's capital.


Who will lead the lecture?

Katarzyna Wójcik-Bąkowska

Legal Counsel, partner in the M&A department of Wardyński & Partners, with extensive experience in handling transactions in the healthcare and biotechnology sectors. Recently, she represented Bio-Rad Laboratories during the acquisition of 100% of the capital of Curiosity Diagnostic sp.zo.o. from Scope Fluidics S.A.

Marcin Pietkiewicz

Legal Counsel, partner at Wardyński i Wspólnicy law firm specializing in the area of capital markets, including M&A transactions on the public companies market. Most recently, he represented QIAGEN N.V. in the acquisition and delisting of shares in Blirt S.A.



EIT Health Lecture

**What makes working together work? –
Principles/ good practices of Equitable
Research Partnerships in Health.**

Equitable partnerships are essential for global health research. Conducting research in partnership with stakeholders (e.g. policy-makers, practitioners, organizations, patients) is a promising and popular approach to improving the implementation of research findings in policy and practice and producing research that ultimately achieves a greater impact when put into practice. At their best, research partnerships provide a mechanism to optimize each partner's strengths, make scientific discoveries and achieve development goals. A better understanding of research partnerships and integrated knowledge translation has implications for future partnerships and collaborative initiatives in practice. Therefore it is important for researchers to take the initiative to ensure that equitable, mutually supportive partnerships are developed from the generation of the initial

research concept through to the project delivery and final dissemination of the research outcomes. During the lecture we will dive deeper into the principles of the equitable partnerships and provide a toolkit for creating a successful partnership, showcasing good practices from the EIT Health


Who will lead the lecture?

Joanna Broy

(Ecosystem Lead for Poland at EIT Health InnoStars) - an expert with extensive experience in healthcare innovations, entrepreneurship education, EU funds and technology transfer. Within EIT Health, one of the largest healthcare innovation networks in Europe, she is responsible for implementing the education 4.0 strategies. Before joining EIT Health, Joanna was the Head of the Acceleration Projects Department at the Centre for Innovation and Technology Transfer Medical University of Lodz

Katarzyna Banyś

Expert on the Horizon Europe program at the Industry Contact Point Medical Technologies and Health with over 15 years of experience in coordinating and implementing framework program projects. For many years, manager of the Regional Contact Point for EU research programs at Wroctaw Center for Technology Transfer (Wroclaw University of Science and Technology), supporting scientists and entrepreneurs in obtaining international research grants.



#CEBioForum2023



**polpharma
biologics**

Polpharma Biologics Lecture

From design to implementation -
challenges of the transition phase in
biotechnological processes.

The speech will cover the topics of challenges during proper planning and preparation for the production of biotechnological products. The speakers will talk about the differences and legal requirements between product development and clinical trials as well as process validation and commercial manufacturing. During the lecture you will learn how to ensure the quality and integrity of data during the product life phases, how to build a quality system that will ensure GMP. At the end, the lecturers will tell you how to efficiently identify the weak points of the process and how to easily eliminate them.


Who will lead the lecture?

Katarzyna Zalejska

Head of Quality Operations, everyone knows the intention of the pharmaceutical industry - to help patients. Katarzyna Zalejska, an experienced SME and Manager in the pharmaceutical industry, fully understands this commitment. Katarzyna holds a Master's degree in Medical Biotechnology from the Medical University of Lodz. She spent 10 years in the Quality departments of both generic and biotech companies. It developed through the Quality Control, Quality Systems and Operational Quality Assurance departments. Since 2020, she has been associated with Polpharma Biologics, initially involved in the design phase - creating a Quality System with a built-in Culture of Data Quality and Integrity, implementing electronic systems and supporting the strategy and Inspection readiness. Recently, as the culmination of large-scale product oversight efforts, she changed her role to a more operational one to actively participate in the launch of their commercial production.

Ewa Rybak

Head of Quality Compliance and Quality System, for 13 years associated with Quality in the pharmaceutical and biotechnology industry. From the beginning of her professional path, she has been associated with the area of Quality Assurance, Quality Compliance and preparation for audits and inspections. As a Senior Audit and Inspection Manager, he is responsible for preparing Polpharma Biologics for certification by the FDA, and also participates in obtaining authorizations for other global markets. He has the qualifications of a Qualified Person. He has been at Polpharma Biologics for over 3 years.



Crido Lecture

Tax savings due to conducting innovative activity.

The lecture will focus on the practical aspects of using the available tax mechanisms to support development activities in enterprises. The speakers, having thorough knowledge of the available range of possibilities, are long-term practitioners of identifying and implementing reliefs in companies, thanks to which taxpayers receive material savings. During the presentation describing the discounts, the speakers will also present, based on examples, how to use the discounts and combine them and what factors determine their safe use.


Who will lead the lecture?

Marek Dałka

Senior Manager, Crido, BIC, has been advising entrepreneurs in obtaining public funds for innovative projects for over twenty years. The main area of his interests are EU subsidies as well as tax reliefs and incentives, such as R&D relief, IP Box.

Urszula Uchmańska

Crido Manager, BIC, is a tax advisor, for many years she gained experience in the field of tax advisory in one from companies called The Big Four, where she primarily advised clients from the financial sector (banks, quasi-banks, insurers, investment funds, etc.).



Mabion S.A

Lecture

**Empowering Biotech: Mabion as a Company
with a Great Workplace Culture**

Mabion is a biotechnology company which is at the forefront of developing cutting-edge technologies and end-to-end solutions. Their team of experienced scientists is focused on developing breakthrough solutions and facing biopharma challenges. They started as a small startup with a clear mission to develop innovative biotechnology solutions to address some of the most pressing medical challenges facing society. However, as they grew, they encountered a range of challenges that threatened our success, including increased competition, changing market dynamics, and regulatory hurdles. During the lecture the speakers will tell what challenges the company had to overcome. They embarked on a transformation journey that involved a complete overhaul of our business strategy, organizational structure, and company culture. This involved reorganizing their teams to improve efficiency, and

implementing new processes and systems to streamline operations. Mabion provides a stimulating and challenging work environment, which fosters personal and professional growth. Mabion also values collaboration and teamwork. The company recognizes that its employees are its most valuable asset, and it fosters a culture of respect and openness where everyone's ideas are valued. We invest in training and development programs that help employees to acquire new skills and stay up-to-date with the latest industry trends. This investment in employee development is not only good for employees but also benefits the company as it enables the company to attract and retain top talent.

“We believe that our history is an example of successfully overcoming challenges; taking advantage of opportunities and openly accepting opportunities to change in today's dynamic business environment of biotechnology and pharmacy”.



Thank You


for being with us

&

see you next year at

#CEBioForum2024

26-27 March ————— 2024, Warsaw



follow us

Central European BioForum



in

f

